Health Care

Thursday's Health Winners & Losers

 

Health stocks followed the broader markets into a refreshing green spell on Thursday amid medical technology and diagnostics earnings.

Big biotechs Amgen (AMGN) and Biogen Idec (BIIB) were up trading up more than 2% each. Also Gilead (GILD) and Genzyme (GENZ) added 1.4% and 1.2% respectively.

In fact, every stock on the Amex biotechnology index, which was up 2.1% at 760.94, read green midday Thursday except for biotech behemoth Genentech (DNA). Its shares were incidentally off by 0.4%, at $67.92.

Away from biotechs, Orthopedic product maker Orthofix International NV (OFIX) said Thursday that its first-quarter profit fell to $3.6 million, or 21 cents a share, from $6.3 million, or 37 cents a share, in the year-ago period.

Revenue rose 9% to $128 million from $117 million, beating expectations of analysts polled by Thomson Financial who expected profit of 9 cents a share on revenue of $122.5 million. The beat prompted a 14.6% rise in the stock, to $35.25.

Also up, Natus Medical (BABY) 6.5% to $20.94 after beating first-quarter earnings estimates and raising guidance. The newborn-care product maker said it earned $2.6 million, or 11 cents a share, up 73% from $1.5 million, and 7 cents a share, in the year-ago quarter. Revenue climbed 36% to $36.9 million, analysts surveyed by Thomson Financial were looking for 10 cents a share, on $35.5 million in revenue.

Natus also upped its first-quarter expectations to 72 cents a share on revenue of $162 million, from previous guidance of 70 cents and $161 million.

TheStreet Premium Services

Jim Cramer
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
OptionsProfits
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Real Money
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn More
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
Dow Jones S&P 500 NASDAQ 10-Year Note
12,419.86 1,313.32 2,837.36 16.25
Oil *
103.00
DOWN
160.83
DOWN
19.10
DOWN
33.63
DOWN
1.06
10 Yr
1.62%
SPDR Gold
151.91
-1.28%
-1.43%
-1.17%
-6.12%
Data delayed 20 minutes

Top Stories and Tools

Articles From

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy.
Podcasts

Connect with TheStreet